Unicycive Therapeutics (UNCY) Share-based Compensation (2020 - 2026)
Unicycive Therapeutics posted quarterly Share-based Compensation of $754000.0 for Q1 2026, up 33.93% year-on-year from $563000.0 in Q1 2025, and down 3.08% on a QoQ basis from $778000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Share-based Compensation data on file, last reported at $754000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 33.93% year-over-year to $754000.0; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 18.44% YoY), and the FY2025 full-year result was $2.6 million, up 12.38% from the prior year.
- Share-based Compensation for Q1 2026 stood at $754000.0, down from $778000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $929000.0 in Q3 2023 and bottomed at $144000.0 in Q2 2022.
- The 5-year median for Share-based Compensation is $563000.0 (2025), against an average of $494647.1.
- The widest annual swing landed in 2022, when Share-based Compensation sank 51.02%; it then jumped 345.14% in 2024.
- A 5-year view of Share-based Compensation shows it stood at $197000.0 in 2022, then jumped by 179.19% to $550000.0 in 2023, then gained by 5.82% to $582000.0 in 2024, then jumped by 33.68% to $778000.0 in 2025, then retreated by 3.08% to $754000.0 in 2026.
- The last three Share-based Compensation figures came in at $754000.0 (Q1 2026), $778000.0 (Q4 2025), and $729000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 754,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 754,000.00 |
| Mar 31, 2026 | 754,000.00 |
| Dec 31, 2025 | 778,000.00 |
| Dec 31, 2025 | 778,000.00 |
| Sep 30, 2025 | 729,000.00 |
| Sep 30, 2025 | 729,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Mar 31, 2025 | 563,000.00 |
| Dec 31, 2024 | 582,000.00 |
| Dec 31, 2024 | 582,000.00 |
| Sep 30, 2024 | 605,000.00 |
| Sep 30, 2024 | 605,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Mar 31, 2024 | 522,000.00 |
| Mar 31, 2024 | 522,000.00 |
| Dec 31, 2023 | 550,000.00 |
| Dec 31, 2023 | 550,000.00 |
| Sep 30, 2023 | 929,000.00 |
| Sep 30, 2023 | 929,000.00 |
| Jun 30, 2023 | 144,000.00 |
| Jun 30, 2023 | 144,000.00 |
| Mar 31, 2023 | 144,000.00 |
| Mar 31, 2023 | 144,000.00 |
| Dec 31, 2022 | 197,000.00 |
| Dec 31, 2022 | 197,000.00 |
| Sep 30, 2022 | 266,000.00 |
| Sep 30, 2022 | 266,000.00 |
| Jun 30, 2022 | 144,000.00 |
| Jun 30, 2022 | 144,000.00 |
| Mar 31, 2022 | 290,000.00 |
| Mar 31, 2022 | 290,000.00 |
| Dec 31, 2021 | 231,000.00 |
| Dec 31, 2021 | 231,000.00 |
| Sep 30, 2021 | 239,000.00 |
| Sep 30, 2021 | 239,000.00 |
| Jun 30, 2021 | 294,000.00 |
| Jun 30, 2021 | 294,000.00 |
| Mar 31, 2021 | 202,000.00 |
| Mar 31, 2021 | 202,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 71,000.00 |
| Sep 30, 2020 | 71,000.00 |
| Jun 30, 2020 | 60,000.00 |
| Jun 30, 2020 | 60,000.00 |